CHECKPOINT THERAPEUTICS INC (CKPT) Stock News
NASDAQ:CKPT - Nasdaq - US1628282063 - Common Stock
CKPT Latest News and Analysis
Adoption of Autonomous Drones Rises for Military Operations Fueled by Cutting-Edge Technology
EQNX::TICKER_START (NASDAQ:ZENA),(NYSE:UAVS),(NASDAQ:RCAT),(NASDAQ:ONDS),(NASDAQ:DPRO),(CSE:DPRO),(NASDAQ:CKPT) EQNX::TICKER_END
Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:CRDF),(NASDAQ:PSNL),(NASDAQ:TEM),(NASDAQ:CKPT) EQNX::TICKER_END
Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses
/PRNewswire/ -- USA News Group News Commentary – The American Cancer Society has published its Advances in Oncology – 2024 Research Highlights, underscoring...
Cancer Care Disruptions Highlight Growing Demand for Innovative Oncology Treatments
/PRNewswire/ -- USA News Group News Commentary – The American Cancer Society recently released its Advances in Oncology – 2024 Research Highlights report that...
FDA Approves Checkpoint Therapeutics' Skin Cancer Drug One Year After Rejection
Checkpoint Therapeutics' Unloxcyt wins FDA approval for advanced cSCC, marking the company's entry into the U.S. market, valued over $1 billion annually.
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)
UNLOXCYT is the first and only FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma...
Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend
/PRNewswire/ -- USA News Group News Commentary – Despite death rates for some cancers being on the decline, there is a global surge in cancer cases among...
Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
Biologics License Application for cosibelimab under review by U.S. FDA PDUFA goal date of December 28, 2024 WALTHAM, Mass., Nov. 12, 2024 (GLOBE...
Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024
Biologics License Application currently under review by U.S. FDA; PDUFA goal date of December 28, 2024...
Checkpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
WALTHAM, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and...
CKPT Stock Earnings: Checkpoint Therapeutics Beats EPS, Beats Revenue for Q2 2024
CKPT stock results show that Checkpoint Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
CKPT Stock Earnings: Checkpoint Therapeutics Beats EPS, Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Checkpoint Therapeutics (NASDAQ:CKPT) just reported results for the second quar...
Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Updates
WALTHAM, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and...
Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma
PDUFA goal date of December 28, 2024 set by FDA...
GC Cell and Checkpoint Therapeutics Advance Collaborative Cancer Research
Collaboration explores the potential synergistic effects of Checkpoint’s anti-PD-L1, cosibelimab, in combination with the autologous T cell therapy,...
Checkpoint Therapeutics Announces $12 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
WALTHAM, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and...
Checkpoint Therapeutics Announces Biologics License Application Resubmission for Cosibelimab
WALTHAM, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and...
Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission
WALTHAM, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and...
CKPT DEADLINE TODAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Before Important June 4 Deadline in Securities Class Action - CKPT
WHY: NEW YORK, NY - (NewMediaWire) - June 4, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) between March 10, 2021 and December 15, 2023, both dates inclusive (the “Class Period”), of the important June 4, 2024 lead plaintiff deadline.
CKPT DEADLINE TODAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Before Important June 4 Deadline in Securities Class Action - CKPT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Checkpoint
/PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Checkpoint Therapeutics, Inc....
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Checkpoint Therapeutics, Inc. (CKPT)
CKPT FINAL DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Before Important June 4 Deadline in Securities Class Action - CKPT
WHY: NEW YORK, NY - (NewMediaWire) - June 3, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) between March 10, 2021 and December 15, 2023, both dates inclusive (the “Class Period”), of the important June 4, 2024 lead plaintiff deadline.
CKPT FINAL DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Before Important June 4 Deadline in Securities Class Action - CKPT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Checkpoint
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Checkpoint
/PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Checkpoint Therapeutics, Inc....
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Checkpoint Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - CKPT
/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Checkpoint Therapeutics, Inc. ("Checkpoint" or the "Company")...
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Checkpoint
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Before Important June 4 Deadline in Securities Class Action - CKPT
/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT)...
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Before Important June 4 Deadline in Securities Class Action - CKPT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.